CD40 ligation converts TGF-β-secreting tolerogenic CD4-8- dendritic cells into IL-12-secreting immunogenic ones

Biochemical and Biophysical Research Communications

Volumn 379, Issue 4, 2009, Pages 954-958

  Zhang, Xueshu ^a   Kedl, Ross M ^b   Xiang, Jim ^a  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Antitumor immunity; CD40 ligation; DC subset; Immunogenic; Tolerogenic

Indexed keywords

ADENOVIRUS VECTOR; CD40 LIGAND; INTERLEUKIN 12; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; C57BL 6 MOUSE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; IMMUNOGENICITY; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; TH1 CELL; TRANSGENIC MOUSE; TUMOR REGRESSION;

ANIMALS; ANTIGENS, CD4; ANTIGENS, CD40; ANTIGENS, CD8; CD40 LIGAND; DENDRITIC CELLS; IMMUNE TOLERANCE; INTERLEUKIN-12; MICE; MICE, INBRED C57BL; NEOPLASMS; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; TH1 CELLS; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 59249094763     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2008.12.179     Document Type: Article

References (26)

1. Moser M., and Murphy K.M. Dendritic cell regulation of TH1-TH2 development. Nat. Immunol. 1 (2000) 199-205
2. McLellan A.D., Kapp M., Eggert A., Linden C., Bommhardt U., Brocker E.B., Kammerer U., and Kampgen E. Anatomic location and T-cell stimulatory functions of mouse dendritic cell subsets defined by CD4 and CD8 expression. Blood 99 (2002) 2084-2093
3. Pooley J.L., Heath W.R., and Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J. Immunol. 166 (2001) 5327-5330
4. Legge K.L., Gregg R.K., Maldonado-Lopez R., Li L., Caprio J.C., Moser M., and Zaghouani H. On the role of dendritic cells in peripheral T cell tolerance and modulation of autoimmunity. J. Exp. Med. 196 (2002) 217-227
5. Belz G.T., Behrens G.M., Smith C.M., Miller J.F., Jones C., Lejon K., Fathman C.G., Mueller S.N., Shortman K., Carbone F.R., and Heath W.R. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissue-associated antigens. J. Exp. Med. 196 (2002) 1099-1104
6. Zhang X., Huang H., Yuan J., Sun D., Hou W.S., Gordon J., and Xiang J. CD4-8- dendritic cells prime CD4+ T regulatory 1 cells to suppress antitumor immunity. J. Immunol. 175 (2005) 2931-2937
7. Liu Y., Bi X., Xu S., and Xiang J. Tumor-infiltrating dendritic cell subsets of progressive or regressive tumors induce suppressive or protective immune responses. Cancer Res. 65 (2005) 4955-4962
8. Grewal I.S., and Flavell R.A. CD40 and CD154 in cell-mediated immunity. Annu. Rev. Immunol. 16 (1998) 111-135
9. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76 (1994) 959-962
10. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
11. Schoenberger S.P., Toes R.E., van der Voort E.I., Offringa R., and Melief C.J. T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature 393 (1998) 480-483
12. Liu Y., Zhang X., Zhang W., Chen Z., Chan T., Ali K., Jia Z., and Xiang J. Adenovirus-mediated CD40 ligand gene-engineered dendritic cells elicit enhanced CD8(+) cytotoxic T-cell activation and antitumor immunity. Cancer Gene Ther. 9 (2002) 202-208
13. Liu Y., Xia D., Li F., Zheng C., and Xiang J. Intratumoral administration of immature dendritic cells following the adenovirus vector encoding CD40 ligand elicits significant regression of established myeloma. Cancer Gene Ther. 12 (2005) 122-132
14. Xiang J., Huang H., and Liu Y. A new dynamic model of CD8+ T effector cell responses via CD4+ T helper-antigen-presenting cells. J. Immunol. 174 (2005) 7497-7505
15. Dunn T.B., and Potter M. A transplantable mast-cell neoplasm in the mouse. J. Natl. Cancer Inst. 18 (1957) 587-601
16. Rolink A., Melchers F., and Andersson J. The SCID but not the RAG-2 gene product is required for S mu-S epsilon heavy chain class switching. Immunity 5 (1996) 319-330
17. Zhang X., Moyana T., Quereshi M., and Xiang J. Conversion of tolerogenic CD4-8- dendritic cells to immunogenic ones inducing efficient antitumor immunity. Cancer Biother. Radiopharm. 21 (2006) 74-80
18. Hao S., Yuan J., and Xiang J. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory. J. Leukoc. Biol. 82 (2007) 829-838
19. Xiang J., and Moyana T. Regression of engineered tumor cells secreting cytokines is related to a shift in host cytokine profile from type 2 to type 1. J. Interferon Cytokine Res. 20 (2000) 349-354
20. Hao S., Liu Y., Yuan J., Zhang X., He T., Wu X., Wei Y., Sun D., and Xiang J. Novel exosome-targeted CD4+ T cell vaccine counteracting CD4+25+ regulatory T cell-mediated immune suppression and stimulating efficient central memory CD8+ CTL responses. J. Immunol. 179 (2007) 2731-2740
21. French R.R., Chan H.T., Tutt A.L., and Glennie M.J. CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat. Med. 5 (1999) 548-553
22. von Leoprechting A., van der Bruggen P., Pahl H.L., Aruffo A., and Simon J.C. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res. 59 (1999) 1287-1294
23. Tutt A.L., O'Brien L., Hussain A., Crowther G.R., French R.R., and Glennie M.J. T cell immunity to lymphoma following treatment with anti-CD40 monoclonal antibody. J. Immunol. 168 (2002) 2720-2728
24. Turner J.G., Rakhmilevich A.L., Burdelya L., Neal Z., Imboden M., Sondel P.M., and Yu H. Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J. Immunol. 166 (2001) 89-94
25. Buhtoiarov I.N., Lum H.D., Berke G., Sondel P.M., and Rakhmilevich A.L. Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J. Immunol. 176 (2006) 309-318
26. Rakhmilevich A.L., Buhtoiarov I.N., Malkovsky M., and Sondel P.M. CD40 ligation in vivo can induce T cell independent antitumor effects even against immunogenic tumors. Cancer Immunol. Immunother. 57 (2008) 1151-1160